 Celcuity Inc NASDAQ: CELC has entered into a global licensing agreement with Pfizer Inc NYSE: PFE, granting Celcuity exclusive rights to Pfizers gedatolisib. The pan-PI3KmTOR inhibitor is currently in Phase 1b trial to treat patients with ERHER2-negative advanced or metastatic breast cancer. 